Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Coronavirus Update:What patients and families need to know

Institute + Division of Blood and Marrow Transplantation

In this reporting period, Catherine M. Bollard, MD, Russell Cruz, MD, PhD, and Patrick Hanley, PhD, joined the Immunology team of the Sheikh Zayed Institute. Dr. Bollard is a senior scientist and a member of the Division of the Blood and Marrow Transplantation and co-directs the Immunology Initiative of the Sheikh Zayed Institute for Pediatric Surgical Innovation.

Under Drs. Bollard and Hanley’s direction, Children’s National established a specialized research team dedicated exclusively to cellular therapy, working in an advanced, sophisticated cGMP facility. The facility adheres to FDA-enforced regulations. The team has rolled out the Program for Cell Enhancement and Technologies for Immunotherapy (CETI), and has performed the hospital’s first treatment using T-cell therapy for a 6-month-old patient with congenital immune deficiency and a life-threatening virus infection.

Dr. Bollard’s research interests focus on different areas including developing cell and gene therapies for (i) patients with cancer, (ii) underlying immune deficiencies and (iii) inflammatory disorders/autoimmune conditions. Dr. Bollard is also head of the non-Hodgkin's lymphoma committee of
the Children’s Oncology group.